L1000 comparisons
Description of feature
From https://www.nature.com/articles/s41467-020-17440-w
L1000 gene expression signatures were taken from either the LINCS Phase 2 data (GEO accession GSE70138, downloaded from http://amp.pharm.mssm.edu/Slicr) or LINCS Phase 1 data (GEO accession GSE92742, downloaded from clue.io). Phase 2 data were used when available (for the compounds trametinib, everolimus, and JQ1), while Phase 1 data were used for the remaining compounds (bortezomib, gemcitabine, and navitoclax). Comparisons were made using the average of the L1000 Level 5 gene expression signatures across all samples for a given drug and the average LFC values across all cell lines from the MIX-Seq experiment for that drug (24 h posttreatment).
This issues solely serves to not forget the idea. It might be revisited at a later time